A case report of postoperative poor drainage of perianal abscess in an obese diabetic patient treated with comprehensive therapy.

Li F, Qin M, Lei Z, Lu Y, Yuan Y, Shao X, Zhao R

Journal of surgical case reports6 May 2026

PMID42100606PMCIDPMC13147442DOI10.1093/jscr/rjag349PepBankPUB-42100606

Summary

Postoperative inadequate drainage of perianal abscess is prevalent in obese patients with diabetes, caused by obesity-related high tissue pressure and diabetes-induced impaired immunity/microcirculation. We report a 25-year-old obese male (BMI 37.9 kg/m²) with newly diagnosed type 2 diabetes who developed recurrent abscess on postoperative Day 3 after surgery for perianal abscess, anal fistula, and mixed hemorrhoids. He was treated with active catheter drainage, ceftriaxone-based targeted anti-infection (guided by Klebsiella pneumoniae culture), and metformin + liraglutide for glucose control. The patient fully recovered with normalized inflammatory markers and blood glucose, without recurrence or anal fistula formation at 1-year follow-up. This validates the efficacy of the comprehensive strategy for high-risk patients with long-term clinical outcomes.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome
In one obese man with T2D and recurrent perianal abscess receiving drainage, ceftriaxone, metformin and liraglutide, inflammatory markers normalized.
In plain wordsIn one obese man with diabetes and perianal abscess, combined drainage, ceftriaxone, metformin and liraglutide accompanied normalized inflammatory markers.
Peptide
Liraglutide
Outcome
Direction not reportedInflammatory markers
Study
n = 1
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
The patient fully recovered with normalized inflammatory markers and blood glucose, without recurrence or anal fistula formation at 1-year follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
We report a 25-year-old obese male (BMI 37.9 kg/m²) with newly diagnosed type 2 diabetes who developed recurrent abscess on postoperative Day 3 after surgery for perianal abscess, anal fistula, and mixed hemorrhoids.
Summary · context
He was treated with active catheter drainage, ceftriaxone-based targeted anti-infection (guided by Klebsiella pneumoniae culture), and metformin + liraglutide for glucose control.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4210060601
02HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome
In one obese man with T2D and recurrent perianal abscess receiving drainage, ceftriaxone, metformin and liraglutide, blood glucose normalized.
In plain wordsIn one obese man with diabetes and perianal abscess, combined drainage, ceftriaxone, metformin and liraglutide accompanied normalized blood glucose.
Peptide
Liraglutide
Outcome
Direction not reportedBlood glucose
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The patient fully recovered with normalized inflammatory markers and blood glucose, without recurrence or anal fistula formation at 1-year follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
We report a 25-year-old obese male (BMI 37.9 kg/m²) with newly diagnosed type 2 diabetes who developed recurrent abscess on postoperative Day 3 after surgery for perianal abscess, anal fistula, and mixed hemorrhoids.
Summary · context
He was treated with active catheter drainage, ceftriaxone-based targeted anti-infection (guided by Klebsiella pneumoniae culture), and metformin + liraglutide for glucose control.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4210060602
03HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome
In one obese man with T2D and recurrent perianal abscess receiving drainage, ceftriaxone, metformin and liraglutide, no perianal-abscess recurrence occurred at 1 year.
In plain wordsIn one obese man with diabetes, combined drainage, ceftriaxone, metformin and liraglutide was followed by no perianal abscess recurrence at one year.
Peptide
Liraglutide
Outcome
Not applicableAbscess recurrence
Study
n = 1
Outcome group
Infection and antimicrobial activity · Infection
Source sentences
Summary
The patient fully recovered with normalized inflammatory markers and blood glucose, without recurrence or anal fistula formation at 1-year follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
We report a 25-year-old obese male (BMI 37.9 kg/m²) with newly diagnosed type 2 diabetes who developed recurrent abscess on postoperative Day 3 after surgery for perianal abscess, anal fistula, and mixed hemorrhoids.
Summary · context
He was treated with active catheter drainage, ceftriaxone-based targeted anti-infection (guided by Klebsiella pneumoniae culture), and metformin + liraglutide for glucose control.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4210060603
04HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome
In one obese man with T2D and recurrent perianal abscess receiving drainage, ceftriaxone, metformin and liraglutide, no anal fistula formed at 1 year.
In plain wordsIn one obese man with diabetes, combined drainage, ceftriaxone, metformin and liraglutide was followed by no anal fistula at one year.
Peptide
Liraglutide
Outcome
Not applicableAnal fistula formation
Study
n = 1
Outcome group
Infection and antimicrobial activity · Gastrointestinal
Source sentences
Summary
The patient fully recovered with normalized inflammatory markers and blood glucose, without recurrence or anal fistula formation at 1-year follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
We report a 25-year-old obese male (BMI 37.9 kg/m²) with newly diagnosed type 2 diabetes who developed recurrent abscess on postoperative Day 3 after surgery for perianal abscess, anal fistula, and mixed hemorrhoids.
Summary · context
He was treated with active catheter drainage, ceftriaxone-based targeted anti-infection (guided by Klebsiella pneumoniae culture), and metformin + liraglutide for glucose control.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4210060604
05HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome
In one obese man with T2D and recurrent perianal abscess receiving drainage, ceftriaxone, metformin and liraglutide, full clinical recovery occurred.
In plain wordsIn one obese man with diabetes and perianal abscess, combined drainage, ceftriaxone, metformin and liraglutide was followed by full recovery.
Peptide
Liraglutide
Outcome
Not applicableFull clinical recovery
Study
n = 1
Outcome group
Overall treatment effect · Whole body
Source sentences
Summary
The patient fully recovered with normalized inflammatory markers and blood glucose, without recurrence or anal fistula formation at 1-year follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
We report a 25-year-old obese male (BMI 37.9 kg/m²) with newly diagnosed type 2 diabetes who developed recurrent abscess on postoperative Day 3 after surgery for perianal abscess, anal fistula, and mixed hemorrhoids.
Summary · context
He was treated with active catheter drainage, ceftriaxone-based targeted anti-infection (guided by Klebsiella pneumoniae culture), and metformin + liraglutide for glucose control.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4210060605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.